Coelho RC, et al. - In this retrospective cohort study with 109 patients who had advanced gastric cancer (GC), researchers assessed the outcomes of first-line treatment with cisplatin 80 mg/m2 on day 1 and fluorouracil (FU) bolus 400 mg/m2 plus leucovorin 20 mg/m2 on days 1, 8, 15, and 22 every 4 weeks (the PFL protocol). The median number of cycles received per patient was four (one to 11). In 6.4% cases and in 14.7% of cases, complete responses and partial responses were achieved, respectively. Median progression-free survival and median overall survival were 6.3 months and 8.3 months, respectively. After 1 year, 34 (31.2%) patients were alive. In 26.6% and 3.7% of patients, grade 3 and 4 adverse events were reported, respectively, with dose reduction necessary in 9.1%. Overall, findings showed the activity of PFL in advanced GC. In institutions with limited resources and/or low budgets, PFL could serve as an alternative for FU continuous infusion protocols.